Disagreement Regarding Additional Product. If the Joint ----------------------------------------- Development Committee or the Joint Steering Committee, as the case may be, does not accept such proposal (unanimously in the case of the Joint Steering Committee), such proposed Additional Product shall not become a Collaboration Product; provided, however, if GSK proposes an Additional Product and Adolor does not desire to Develop or Commercialize such proposed Additional Product in the United States, GSK may Develop and Commercialize such proposed Additional Product in the ROW subject to Section 4.3.3.
Appears in 5 contracts
Samples: Collaboration Agreement (Adolor Corp), Collaboration Agreement (Adolor Corp), Collaboration Agreement (Adolor Corp)
